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Oncological treatment is often associated with a wide range of adverse effects. The article focuses on systemic 
complications that may occur during the hormonal therapy of prostate and breast cancer. Considering that current 
treatments are increasingly effective, the number of patients suffering from early and remote complications of can-
cer therapy can be expected to rise. Many undergo radical treatment and in this group in particular, close attention 
should be paid to the prevention, early diagnosis, and treatment of adverse effects. Hormonal disorders and their 
complications considerably affect the quality of life and life expectancy by upsetting general systemic homeostasis.
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Hormonal therapy of patients with prostate 
cancer
The incidence rate of prostate cancer is rapidly on the 
rise both in Poland and beyond as a side effect of increasing 
life expectancy and a significant improvement in detection 
methods. According to the National Cancer Registry, over 
12 thousand new cases were diagnosed in Poland in 2013, 
which represents more than a twofold increase over the last 
decade. Prostate cancer is the second most frequent cancer 
and the third most frequent cause of cancer death in the 
male population. Over the last decades, a significant impro-
vement has been observed both in radical therapy and in 
the treatment of systemic disease. As a consequence, there 
has also been a systematic growth in the number of prosta-
te cancer patients who survive over many years; for these 
individuals, the quality of life is of paramount importance 
and it is largely determined by the presence of treatment-
-related adverse effects, some caused by hormonal therapy.
Prostate cancer is an androgen-dependent condition. 
Androgens are secreted primarily by the testicles, which 
produce nearly 95% of these hormones; the remaining 5% 
are generated by the adrenal glands. The androgen-de-
pendence of prostate cancer makes hormonal therapy one 
of the most effective treatment methods. It may involve 
surgical castration (bilateral orchiectomy), pharmacological 
castration (GnRH agonists or antagonists), steroid receptor 
blocking with antiandrogens, or androgen biosynthesis in-
hibition. The objective of hormonal therapy is to inhibit the 
progression-stimulating impact of androgens on cancer-cell 
receptors. The desired effect may be achieved by lowering 
the concentration of androgens in the system or blocking 
the androgen receptor. In patients with systemic disease, 
hormonal therapy is continued until disease progresses or 
unacceptable toxicity symptoms set in, which often means 
many years or even a lifetime on medication. Locally advan-
ced disease is treated with hormonal therapy in sequence 
with radiotherapy or surgery. In these cases, the time of 
exposure to hormonal drugs is limited. The basic adverse 
effects of hormonal therapy in prostate cancer patients are 
directly related to androgen deficiency, which adversely 
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affects the quality of life and induces secondary complica-
tions that may lead to disease and even death.
Early symptoms of androgen deficiency include: fatigue, 
hot flushes, gynecomastia, hair loss, increased fatty tissue, 
bone loss, lipid disorders, hyperinsulinemia, and loss of 
libido or erectile dysfunctions. Sleep and memory disorders 
may also occur, and in extreme cases, low mood associated 
with treatment may lead to depression.
Late symptoms include osteoporosis, type 2 diabetes, 
the metabolic syndrome X, and cardiovascular conditions.
The specific profile of adverse effects depends on the 
method of hormonal treatment. Unlike surgical and pharma-
cological castration, non-steroid antiandrogens do not lower 
the concentration of testosterone, which allows patients 
to maintain sexual activity, as well as reduces the risk of 
atherosclerosis and metabolic complications. In comparison 
with other hormonal methods, the treatment has a positive 
effect on the quality of life, especially at a younger age, and 
lowers the risk of treatment-related conditions. It should be 
kept in mind, however, that its effectiveness will resemble 
that of pharmacological castration only in monotherapy 
with high doses of bicalutamide (150 mg per day). In pa-
tients with prior cardiovascular disease, extreme caution 
is advisable during the long-term administration of LHRH 
analogues. Bicalutamide at a daily dose of 150 mg may be 
considered on the basis of EPC test results [1, 2]. This course 
of treatment, however, is not recommended for routine use 
in clinical practice [3].
Drugs from the group of GnRH agonists result in a fle-
eting rise in testosterone levels, which increases pain and 
raises the risk of spinal cord compression and urine retention 
in advanced cancer patients. Administering anti-androgens 
at least 3 days before the introduction of the LHRH analogue 
reduces but does not eliminate the risk of these events.
The administration of GnRH antagonists causes an im-
mediate testosterone suppression, and, in comparison with 
agonists, drugs from this group are twice more likely to 
cause cardiovascular complications. For this reason, caution 
is recommended while qualifying patients with prior cardiac 
disorders for hormonal therapy in general, and with the use 
of GnRH antagonists in particular.
Hot flushes and gynecomastia 
Hot flushes occur in as many as 75% of patients under-
going hormonal therapy for prostate cancer [4]. Even though 
the symptom does not affect the overall survival rate, it does 
have a significant impact on the quality of life. Hot flushes 
result from malfunctions in hypothalamic thermoregula-
tory centers, which are caused by androgen deficiency. By 
inhibiting the secretion of the luteinizing hormone (LH), 
cyproterone acetate may help reduce these sensations 
during hormonal therapy with LHRH analogues. Parallel 
treatment with cyproterone acetate and medroxyproge-
sterone acetate was studied in a randomized double-blind 
clinical trial, which showed that the combination of the two 
drugs leads to a considerable reduction in hot flushes after 
4 weeks of treatment [5]. Another trial demonstrated that 
the administration of gabapentin during hormonal therapy 
reduces hot flushes by 50% [4].
Impaired cognitive function; low mood 
and depression 
Nelson et al. showed that 47–69% of patients treated 
with hormonal therapy experience a deterioration in at 
least one cognitive function [6]. It should be kept in mind, 
however, that treatment-related fatigue and hot flushes 
as such may also affect cognitive functioning. Treatment 
may affect short-term and spatial memory. Carrier et al. 
observed a significantly lower mood, greater irritability, and 
depression in patients treated with hormonal therapy [7], 
while Lee et al. recorded that they were considerably more 
likely to suffer from depression than the untreated group 
and the control group of healthy men [8].
Not all complications subside after the end of adjuvant 
hormonal treatment. 
Metabolic complications of hormonal therapy
At physiological concentrations, androgens help ma-
intain the normal state of homeostasis in the body; they 
contribute to the growth of bones and muscles and and 
decrease the fatty tissue. Hormonal therapy, however, has 
the opposite effect. An increase in fatty tissue leads to in-
sulin-resistance and, as a consequence, to the develop-
ment of diabetes, lipid disorders, hypertension, and cardiac 
complications. The co-morbidity of obesity, hypertension, 
diabetes, and lipid disorders is defined as the metabolic 
syndrome (Fig. 1).
Table I. Androgen deficiency complications 
Androgen deficiency complications
Early:
Fatigue
Hot flushes
Sexual disorders (loss of libido, erectile dysfunction)
Gynecomastia, mammary gland pain 
Hair loss
Increased fatty tissue; bone loss 
Lipid disorders (increased cholesterol, LDL and TG; reduced HDL)
Hyperinsulinemia
Sleep and memory disorders
Low mood, depression
Late:
Osteoporosis, bone fractures
Type 2 diabetes
Metabolic syndrome
Cardiovascular conditions
Ischemic heart disease, heart attack
Venous thromboembolism, pulmonary embolism, brain stroke 
208
In the Polish population, the metabolic syndrome affects 
c. 20% of adults (22% of women and 18% of men), and its 
incidence rate increases with age. It is estimated to occur 
in c. 5.7 million people in Poland and significantly increases 
the risk of atherosclerosis and cardiovascular disease [9].
Prostate cancer patients treated with radiotherapy com-
bined with adjuvant hormonal therapy, regardless of the 
length of treatment, are twice more likely to be diagnosed 
with the metabolic syndrome than patients treated with 
radiotherapy alone [10].
Morote et al. observed a significant rise in individual 
components of the metabolic syndrome: abdominal obe-
sity, BMI disorders, glucose, triglycerides and cholesterol in 
prostate cancer patients treated with hormonal therapy. 
The incidence of a full-blown metabolic syndrome has not 
been observed to grow significantly over the term of twelve 
months [11].
Smith et al. determined that GnRh agonists increase 
fatty tissue, insulin resistance, and triglyceride levels [12]. 
Unlike the classical metabolic syndrome, the administration 
of GnRH agonists is associated with an increase of subcuta-
neous fatty tissue, HDL levels, and adiponectin [13].
Hormonal therapy induces the growth of fat cells; this 
fuels the production of protein molecules known as adipo-
kines, which lead to the gradual atrophy of muscle tissue. 
The latter, through myokines, further increases the volume 
of fatty tissue and leads to bone loss. These interactions 
are further associated with increased insulin resistance, 
which raises the risk of type 2 diabetes, lipid disorders, and 
cardiovascular complications.
Primary hormonal therapy of prostate cancer patients 
increases the risk of diabetes by 60% [14]. Type 2 diabetes 
is more frequent during long-term hormonal therapy as 
compared with untreated control groups (44% vs 12%) [15]. 
Low testosterone levels strongly correlate with the risk 
of the metabolic syndrome, regardless of BMI; the risk is 2.7 
times greater [16].
Cardiac complications
Whether the risk of cardiovascular disease is higher in 
patients treated with hormonal therapy remains controver-
sial. Some studies indeed show a greater incidence of ische-
mic heart disease, heart attack, and arrhythmias [17–22].
In a special population-based study, Keating et al. deter-
mined that treatment with GnRH agonists involves a signi-
ficantly higher risk of diabetes and cardiovascular compli-
cations (ischemic heart disease, heart attack, cardiac arrest 
and stroke) [23], but other studies have failed to confirm 
a statistically significant correlation [24–26].
In a metaanalysis of 8 randomized trials, Nguyen et al. 
did not observe a heightened risk of cardiovascular compli-
cations in short-term (under 6 months) or long-term (more 
than 3 years) hormonal therapy [27]. In comparison with ra-
diotherapy alone, short-term adjuvant hormonal treatment 
following radical radiotherapy does not seem to increase 
the risk of these events [28].
Osteoporosis
Hormonal therapy reduces the mineral density of bones, 
leads to the development of osteopenia and osteoporosis, 
and increases the risk of pathological fractures.
As many as 40% of patients suffer from osteopenia, and 
11% — from osteoporosis [29], even before the beginning 
of hormonal treatment. Prostate cancer usually affects older 
ADT
Insulin resistance ↓ of muscle mass
↓ of bone mass
Hypertension
HyperlipidemiaType 2 diabetes
Osteoporosis
Myokines
Adipokines
Myokin
↑ of fatty tissue
Figure 1. Metabolic complications of androgen deprivation therapy (ADT)
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patients and the loss of bone mass is related to the normal 
physiological ageing process. 
During hormonal therapy, the annual loss of mineral 
density amounts to 2–8% in the lumbar section of the spine 
and 1.8–6.5 % in the neck of the femur [30].
The incidence rate of osteoporosis increases from 36 
to 80% after 10 years of hormonal therapy, and after that, 
osteopenia or osteoporosis can be expected to develop in 
all treated individuals [31].
Bone complications are diagnosed in c. 49% of prostate 
cancer patients with bone metastases. Hormonal therapy 
increases the risk of these complications due to its negative 
effect on mineral density [32].
The remodeling of bone tissue is a process that lasts 
over a lifetime. In adults, c. 10% of the total bone mass is 
remodeled within a single year. A proper balance between 
the processes of osteogenesis and resorption helps prese-
rve the normal structure of the bone system; such balance 
is maintained thank to the RANKL/RANK/OPG pathway. To 
prevent bone complications in hormonal therapy, zoledro-
nic acid (from the bisphosphonate group) or a monoclonal 
antibody, denosumab, may be used. It is also essential to 
administer calcium and vitamin D3 supplements.
Bisphosphonates are absorbed by the calcium-rich bone 
tissue by binding with calcium ions and stored in the bone 
tissue until absorbed by osteoclasts in the endocytic pro-
cess, which causes these cells to undergo apoptosis. A meta-
analysis that studied the effectiveness of bispohosphonates 
in hormonal therapy of prostate cancer showed a significant 
reduction in the risk of fractures and osteoporosis. The gre-
atest effectiveness was associated with zoledronic acid, 
which has been registered for use in the prevention of bone 
complications in patients with bone metastases [32, 33].
Denosumab is a human monoclonal antibody directed 
against the RANK receptor ligand. By binding to RANKL, it 
neutralizes the ligand and prevents its attachment to RANK 
and the differentiation of osteoclasts, which consequently 
inhibits bone resorption. Denosumab can be used to pre-
vent the loss of bone mass in the course of hormonal abla-
tion in prostate cancer patients at a higher risk of fractures 
(age > 70 years or < 70 years with the BMD T-score in the 
lumbar section of the spine, hip, or neck of the femur <–1.0 
or osteoporotic fracture in the interview). The effectiveness 
of the drug was demonstrated in the HALT clinical trial: 
denosumab helped increased mineral density and reduced 
the risk of new fractures by 62% after 3 years of use [34].
Selective estrogen receptor modulators (SERMs) also 
help reduce bone loss by 50% after 2 years of treatment 
[35, 36].
Systemic complications of hormonal treatment 
in women 
The beginnings of breast cancer treatment date back 
to the 19th century, when surgical oophorectomy was first 
introduced as a therapy. Systematic advancement and deve-
lopment of molecular biology helped to determine the role 
of estrogen and progesterone receptors in the progression 
of the disease, which meant that hormonal treatment could 
be applied in routine medical practice. Hormonal therapy 
inhibits the systemic impact of estrogens and progesto-
gens on cells, including cancer cells, that express relevant 
hormonal receptors. Estrogens can be blocked by inhibiting 
gonadotropins or removing their source (e.g. by the use of 
LHRH agonists, hypophysectomy), blocking the estrogen 
receptor, or inhibiting the peripheral synthesis of estrogen 
precursors, i.e. androgens (Fig. 2) [37, 38].
Castration (surgical, radiological)
Adrenalectomy
removal of the main
source of estrogen
Anti-estrogens: steroid  
and non-steroid
Steroid and non-steroid aromatase
inhibitors
LHRH agonists, progestogens
•
•
blocking the estrogen receptor•
inhibiting the peripheral synthesis 
of estrogens
•
blocking gonadotropin activity
Figure 2. Hormonal therapy — mechanism of action
210
Tamoxifen is the oldest drug used both in adjuvant the-
rapy, and in patients with advanced breast cancer. Classified 
as a non-steroid anti-estrogen — selective estrogen receptor 
modulator (SERM), the substance has an agonistic effect on 
estrogen receptors. Its efficacy crucially depends on the 
transformation of the prodrug into its active form, which, 
according to the relevant literature, shows a 30–100 greater 
anti-estrogen activity. Tamoxifen is metabolized in the liver 
by the cytochrome P450 enzyme system into endoxifen 
or 4-hydroxytamoxifen [39–42], and many isoforms of the 
cytochrome P450 enzymes are known to be involved in the 
process. It should be noted, however, that its actual clinical 
effectiveness depends on the concentration of endoxifen 
in the cytoplasm. Literature suggests that patients treated 
with tamoxifen show higher levels of endoxifen than of 
4-hydroxytamoxifen. Endoxifen degrades the estrogen re-
ceptor by proteasomes, whereas 4-hydroxytamoxifen and 
N-desmethyl tamoxifen stabilize it [40, 43, 44].
Drugs from the aromatose inhibitor (AI) group can be 
divided in terms of chemical structure into steroid inhibitors 
(anastrozole and letrozole) and non-steroid inhibitors (exe-
mestane), and their role is to inhibit the process by which 
androstendion is transformed into estrogen, occurring pri-
marily in the fatty tissue, liver, adrenal glands, muscles, and 
glandular breast tissue. The inhibition of the aromatization 
process is estimated to reduce estrogen to undetectable 
levels. It should be kept in mind, however, that the effects 
of AIs are selective and reversible for steroid inhibitors, but 
irreversible for non-steroid types [37, 38].
In order to prevent the spread of the disease, breast 
cancer patients of premenopausal age undergo surgical 
castration or hormonal therapy based on LHRH analogues. 
Systemic treatment has similar therapeutic outcomes with 
the sole difference that, unlike surgery, it is reversible. LHRH 
analogues affect the function of the hypothalamic-pituitary 
system. Initially, i.e. for a period of about two weeks, FSH 
and LH concentration in the blood increase; subsequently, 
as a  consequence of the the feedback mechanism, their 
secretion is inhibited and ovary function decreases, resulting 
in a drop in estrogen levels [37, 38].
Due to their impact on the entire organism, adverse 
side-effects may affect many organs and depend on the 
type of drug used in treatment. 
Low estrogen symptoms
One of the most frequent adverse effects of SERMs (se-
lective estrogen receptor modulators) includes vasomotor 
symptoms, which occur regardless of the age of the patient 
[37]. Literature indicates that approximately two thirds of all 
patients suffer from hot flushes, while 44% experience noc-
turnal sweating and sleep disorders [46]. Couzi et al. showed 
that out of 190 breast cancer patients of post-menopausal 
age, approximately 2/3 suffered from hot flushes. 29% rated 
their intensity as low and 37% as medium; the remaining 
34% of women experienced severe symptoms [47]. Carpen-
ter observed hot flushes in 65% patients in a group of 114 
women (with the median age of 58.8) who had completed 
radical treatment and were put on adjuvant tamoxifen-
-based therapy. Of all women included in the study, 59% 
described their symptoms as severe. Hot flushes were more 
frequent in patients treated with tamoxifen alone (72%) and 
those receiving chemotherapy (78%) [48].
Literature suggests that a drop in estrogen levels leads 
to the malfunctioning of the hypothalamic thermoregula-
tory center, peripheral circulation, and perspiration. Animal 
testing demonstrated that disturbances in norepinephrine 
secretion in the hypothalamus may affect the thermoregu-
latory center and intensify hot flushes. It is often emphasi-
zed that the stimulation of the serotonin receptor 5-HT2a 
induces hyperthermia, while the stimulation of 5-HT1a lo-
wers body temperature. The influence of estrogens on the 
expression and activation of 5-HT receptors has not been 
entirely explained [49, 50]. The results of the ZEBRA clinical 
trial, which studied 1640 patients, showed that those treated 
with goserelin for two years experienced an increase in the 
intensity of hot flushes, which subsided once the drug was 
discontinued [51]. In another clinical trial, where 149 pa-
tients were randomly assigned to four groups (treated with 
goserelin, tamoxifen, tamoxifen and goserelin, and a control 
group, respectively), increased vasomotor symptoms were 
observed in groups treated with goserelin and goserelin and 
tamoxifen, as compared to the control group [51].
Clinical trials indicate that hot flushes and other vasomo-
tor symptoms related to aromatase inhibitors (AIs) are not 
very severe. An experiment with 4742 breast cancer patients 
randomly assigned to the five-year adjuvant therapy with 
tamoxifen or exemestane (a steroid aromatase inhibitor) 
showed no differences between the two groups in terms of 
vasomotor effects after two years; the figures were 39.6% 
and 42%, respectively [52]. Another trial with 5187 breast 
cancer patients treated with letrozole or placebo, following 
a five-year tamoxifen-based therapy, demonstrated a signi-
ficant intensification of hot flushes in the letrozole group 
(47.2%) as compared to the control group (40.5%). 4.5% of 
patients discontinued treatment with letrozole because of 
these side effects, while the corresponding figure for the 
placebo group was 3.6%. The difference was not statistically 
significant [53].
Treatment of vasomotor symptoms
The treatment of vasomotor symptoms induced by 
hormonal therapy can be difficult. Some authors recom-
mend dietary modifications, such as increasing the intake 
of spicy food, coffee, black tea, or black cohosh. Clonidine, 
bromocriptine, and vitamin E were not shown to be effec-
tive. It would seem that optimal outcome is ensured by the 
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simultaneous use of selective serotonin reuptake inhibitors 
(SSRIs) and selective norepinephrine reuptake inhibitors 
(SNs). Some authors report that c. 25% of patients treated 
with tamoxifen also takes drugs from the SSRI group, such 
as fluoxetine, paroxetine or venlafaxine. It should be kept 
in mind, however, that some might enter into various inte-
ractions and affect CYP2D6 metabolism, which may lead 
to a decrease in the concentration of endoxifen, the active 
metabolite of tamoxifen, and thus reduce treatment efficacy. 
It is believed that drugs from the fluoxetine and paroxetine 
group are strong CYP2D6 enzyme inhibitors. Weak inhibitors 
include sertraline, citalopram, and venlafaxine [48].
In a study devoted to the determinants of tamoxifen-based 
treatment in breast cancer, Wieczorek quotes the results of 
a trial presented at the Congress of the American Society of Cli-
nical Oncology (ASCO) in 2009, which showed that the two-year 
risk of relapse in a group of patients treated with tamoxifen alo-
ne equaled 7.5%, while the corresponding figure for a group in 
which the drug was combined with a strong CYP2D6 inhibitor 
was 13.9%. These data were not confirmed by the analysis of 
the Dutch PHARMO database conducted by Dezentje, but it 
should be noted that the median treatment time in Aubert’s 
trial was 255 days, as compared to only 60 in the Dutch study, 
which may have influenced the final results [40].
Quality of life
Hormonal treatment inarguably affects the quality of 
life of breast cancer patients, changing variables such as 
emotional state (inducing low mood, anxiety disorders, 
and depression), sexual function, and causing fatigue. It is 
often difficult to tell whether these events are the conse-
quence of the cancer or its treatment. In 1998, Carpenter 
concluded that the presence of vasomotor symptoms only 
marginally reduces the quality of life [46], but subsequent 
observations clearly confirmed a significant drop in QoL 
parameters in breast cancer patients with postmenopausal 
symptoms [48]. In a clinical analysis designed to assess the 
impact of vasomotor symptoms on breast cancer patients, 
Stein observed a much higher incidence of fatigue and sleep 
disorders in women of postmenopausal age. It should be no-
ted, however, that the application of the study was limited, 
because of the relatively small size and homogeneity of the 
study group [54]. Mourits, on the other hand, demonstrated 
that tamoxifen had a negative impact on libido and sexual 
activity, causing vaginal dryness in 40% and dyspareunia in 
30% of patients (Fig. 3) [54–56].
Bone and joints disorders. Bone mineral density 
(BMD) disorders 
BMD disorders are one of the more frequent adverse 
effects of hormonal therapy. Their intensity depends on 
the type of treatment and patient age, e.g. postmenopau-
sal women treated with tamoxifen actually experience an 
improvement in bone density and a lower risk of fractures, 
while in premenopausal subjects bone loss not only during 
treatment with tamoxifen but also after pharmacological or 
surgical oophorectomy.
Increased density loss, up to 17.3% over 3 years, is ob-
served in postmenopausal women treated with aromatase 
inhibitors, and bilateral oophorectomy reduces bone mass to 
c. 20% within 18 months. The process progresses over time. 
In contrast, bone loss in healthy postmenopausal patients is 
not greater than 3% per year. The risk of fractures in postme-
nopausal patients treated with aromatase inhibitors is estima-
ted to be more than 30% greater than in healthy women of 
similar age [57]. Hadiji indicates that the loss of bone density 
in healthy postmenopausal women equals c. 1% per year, as 
compared to 2% for AI-treated patients [58].
The mechanism responsible for the loss of bone density 
as a result of AI treatment is the dysfunction of the RANK 
pathway. The RANK pathway controls the processes of bone 
remodeling, i.e. resorption and stratification, based on ele-
ments such as the receptor activator of nuclear factor NF-kB 
(RANK), receptor activator of nuclear factor NF-kB ligand 
(RANKL), and osteoprotegerin (OPG) [37, 38]. The role of 
cytokines (IL-1a, IL-6, IL-11, TNF-a) and glucocorticosteroids 
is also important. The activation of the RANK pathway is 
conditioned by the activity of the ligand on the surface of 
osteoclasts, which activates the processes that stimulate 
their survival and maturation [59].
It cannot be ruled out that the greater incidence of 
bone events during treatment with aromatase inhibitors 
has to do not just with the drug, but also with the fact that 
the therapy is primarily used in women over the age of 50, 
when physiological menopause steps up the processes of 
bone loss.
Reduced size
of adrenal glands
Decreased
androgen levels
Libido loss
Emotional disorders
Vaginal dryness 
Discomfort, pain during intercourse
Figure 3. Libido disorders
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Based on a large prospective clinical trial with postme-
nopausal breast cancer patients treated with AIs, Hadji sho-
wed that the most important risk factors of bone fracture 
included AI intake, T score < 1.5, age > 65 years, reduced 
BMI (< 20 kg/m2), bone brittleness after age 50, a family 
history of hip fracture, oral administration of corticostero-
ids over a period of more than 6 months, and tobacco use. 
The T score was calculated based on the FRAX algorithm. It 
should be noted that the latter is not specifically designed 
for cancer patients, which is why it does not account for 
AI intake as a risk factor; rather, it estimates the 10-year 
risk of bone fracture in postmenopausal women, with or 
without BMD assessment [58, 60]. Based on the above, 
Coleman et al. published treatment guidelines for breast 
cancer patients at risk of aromatase inhibitor-associated 
bone loss (AIBL) and bone fracture. All women are recom-
mended to engage in controlled physical exercise, such as 
walking, and take calcium and vitamin D3 supplements at 
a dose of no less than 1000 IU per day (preferably: 2000 IU 
per day) [60, 61]. Many expert groups also emphasize the 
importance of bisphosphonates in AIBL prevention. Results 
of the Z-FAST study, which assessed the effectiveness of 
5-year treatment with zoledronic acid, showed a statisti-
cally significant (p ≤ 0.0003) delay in the onset of bone loss 
[lumbar spine (LS) and total hip] in comparison with the 
baseline. Treatment time was not defined. Some authors 
recommend a maximum of 2 years, others emphasize that 
it should not extend beyond the duration of AI-based 
therapy. The guidelines of the ASCO (American Society 
of Clinical Oncology) do not specify the recommended 
treatment time either [6, 60].
Determined at reliability levels II and III, indications for 
the use of denosumab in AIBL prevention are not clear. “The 
Hormone Ablation Bone Loss Trial in Breast Cancer (HALT-
-BC)”, which assessed its effectiveness in a group of 252 
early breast cancer patients, demonstrated a statistically 
significant improvement in bone density (7.6%, p = 0.0001) 
in women treated with denosumab as compared to placebo. 
These results, however, should be interpreted with caution 
on account of the heterogeneity of the patient group (e.g. 
the intake of different AIs, different treatment time). More 
promising findings were provided by “The ongoing Au-
strian Breast and Colorectal Cancer Study Group Trial-18” 
(ABCSG-18), which demonstrate the effectiveness of de-
nosumab in improving bone density during AI adjuvant 
treatment [55, 60, 61].
Other hormonal treatment complications 
in women
Tamoxifen-based hormonal therapy may increase the 
risk of endometrial cancer. A large study conducted by the 
NSABP estimated that the annual risk of disease equals 
1.7 out of 1000 women (18), but that treatment benefits 
considerably outweigh the associated risk [62]. Swerdlow, 
on the other hand, showed that the risk of endometrial 
cancer in patients treated with tamoxifen equaled 2.4 (odds 
ratio [OR] = 2.4; 95% confidence interval [CI] = 1.8–3.0) and 
increased as a function of treatment length (five or more 
years); the results were statistically significant p < 0.001 (OR 
= 3.6, 95% CI = 2.6–4.8). The risk was comparable in pre- and 
postmenopausal women (OR = 2.0, 95% CI = 1.1–3.4) and 
in women under the age of 45 who have not undergone 
oophorectomy (OR = 2.0, 95% CI = 1.2–3.5) [62].
Tamoxifen is also associated with a higher risk of throm-
boembolism. The BIG 1-98 study showed a statistically si-
gnificant (p < 0.001) difference in the incidence of embolic 
complications in the group treated with the drug (3.5%), as 
compared to the group that received letrozole (1.5%) [63].
Conclusion
Hormonal therapy is the oldest targeted treatment me-
thod, allowing to increase survival rates not only in radical 
treatment but also in systemic prostate and breast cancer 
patients. Associated metabolic complications during its 
course, however, may contribute to higher cardiac disease 
mortality rates. The risk of osteoporosis and pathological 
fractures in men and women who undergo hormonal the-
rapy is also greater than in the general population, and the 
presence of these complications considerably reduces the 
quality of life. For this reason, it is essential to keep in mind 
the importance of symptom prevention, early diagnosis, and 
treatment, with a view to improving both QoL parameters 
and patient survival. Patients should be advised to quit 
smoking, eat a proper diet, keep a healthy body weight and, 
as much as possible, maintain ongoing physical activity. All 
patients should also be regularly tested for blood pressure, 
lipid levels, and glycemia, and take vitamin D3 supplements 
in order to prevent osteoporosis. A correct diagnosis and 
treatment of treatment-related adverse effects allows to 
improve the quality of life in the patient group.
Conflict of interest: none declared
Beata Jagielska, MD, PhD
Department of Diagnostic Oncology and Cardioncology 
Maria Skłodowska-Curie Memorial Cancer Centre  
and Institute of Oncology
Roentgena St. 5
02–781 Warszawa, Poland
e-mail: bjagielska@coi.waw.pl
Received: 10 Mar 2016  
Accepted: 31 Oct 2016
References
1. Iversen P, McLeod DG, See WA et al. Antiandrogen monotherapy in 
patients with localized or locally advanced prostate cancer: final results 
from the bicalutamide Early Prostate Cancer programme at a medium 
follow-up of 9.7 years. BJU Int 2010; 105: 1074–1081.
213
2. Horwich A, Hugosson J, de Reijke T et al. Prostate cancer: ESMO Con-
sensus Conference Guidelines 2012. Ann Oncol 2013; 24: 1141–1162.
3.  NCCN Guidelines. Prostate Cancer, Version 3.2016.
4. Loprinzi CL, Dueck AC, Khoyratty BS et al. A phase III randomized, dou-
ble-blind, placebo-controlled trial of gabapentin in the management 
of hot flashes in men (N00CB). Ann Oncol 2009; 20: 542–549.
5. Irani J, Salomon L, Oba R et al. Efficacy of venlafaxine, medroxyproges-
terone acetate, and cyproterone acetate for the treatment of vasomotor 
hot flushes in men taking gonadotropin- releasing hormone analogues 
for prostate cancer: a double-blind, randomised trial. Lancet Oncol 
2010; 11: 147–154.
6. Nelson CJ, Lee JS, Gamboa MC et al. Cognitive effects of hormone thera-
py in men with prostate cancer: a review. Cancer 2008; 113: 1097–1106.
7. Cherrier MM, Aubin S, Higano CS. Cognitive and mood changes in men 
undergoing intermittent combined androgen blockade for non-meta-
static prostate cancer. Psychooncology 2009; 18: 237–247.
8. Lee M, Jim HS, Fishman M et al. Depressive symptomatology in men 
receiving androgen deprivation therapy for prostate: a controlled 
comparision. Psychooncology 2015; 24: 472–477.
9. Sieradzki J. Zespół metaboliczny. In: Interna Szczeklika: podręcznik 
chorób wewnętrznych. Kraków: Wydawnictwo Medycyna Praktyczna, 
2012: 1360–1361.
10. Samper Ots PM, Garcia JL, Kavadoy YR et al. SIMBOSPROST: Prevalence 
of metabolic syndrome and osteoporosis in prostate cancer patients 
treated with radiotherapy and androgen deprivation therapy: a mul-
ticentre, cross-sectional study. Rep Pract Oncol Radiother 2015; 20: 
370–376.
11. Morote J, Gomez-Caamano A, Alvarez-Ossorio JL et al. The metabolic 
syndrome and its components in patients with prostate cancer on 
androgen deprivation therapy. J Urol 2015; 193: 1963–1969.
12. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined 
androgen blockade for prostate cancer. J Clin Endocrine Metab 2006; 
91: 1305–1308.
13. Smith MR, Lee H, McGovern F et al. Metabolic changes during gonadotro-
pin-releasing hormone agonist therapy for prostate cancer: differences 
from the classic metabolic syndrome. Cancer 2008; 112: 2188–2194.
14. Tsai HT, Keating NL, Van Den Eden SK et al. Risk of diabetes among 
patients receiving primary androgen deprivation therapy for clinically 
localized prostate cancer. J Urol 2015; 193: 1956–1962.
15. Basaria S, Muller DC, Carducci MA et al. Hyperglycemia and insulin re-
sistance in men with prostate carcinoma who receive androgen-depri-
vation therapy. Cancer 2006; 106: 581–588.
16. Laaksonen D, Niskanen L, Punnonen K et al. Sex hormones, inflam-
mation and the metabolic syndrome: a population-based study. Eur J 
Endocrin 2003; 149: 601–608.
17. Kohutek ZA, Weg ES, Pei X et al. Long-term impact of androgen-depri-
vation therapy on cardiovascular morbidity after radiotherapy for 
clinically localized prostate cancer. Urology 2016; 87: 146–152.
18. Davis MK, Rajala JL, Tydesley S et al. The prevalence of cardiac risk factors 
in men with localized prostate cancer undergone androgen depriva-
tion therapy in British Columbia, Canada. J Oncol 2015; 2015: 820403.
19. Carnerio A, Sasse AD, Wagner AA et al. Cardiovascular events associated 
with androgen deprivation therapy in patients with prostate cancer: 
a systemic review and meta-analysis. World J Urol 2015; 33: 1281–1289.
20. D’Amico AV, Denham JW, Crook J et al. Influence of androgen suppres-
sion therapy for prostate cancer on the frequency and timing of fatal 
myocardial infarctions. J Clin Oncol 2007; 25: 2420–2425.
21. Levine GN, D’Amico AV, Berger P et al. Androgen-deprivation therapy 
in prostate cancer and cardiovascular risk: a science advisory […]. CA 
Cancer J Clin 2010; 60: 194–201.
22. Saigal CS, Gore JL, Krupski TL et al. Androgen deprivation therapy 
increases cardiovascular morbidity in men with prostate cancer. Cancer 
2007; 110: 1493–1500.
23. Keating NL, O’Malley AJ, Freedland SJ et al. Diabetes and cardiovascular 
disease during androgen deprivation therapy: observational study 
of veterans with prostate cancer. J Natl Cancer Inst 2010; 102 : 39–46.
24. Azvolinsky A. Androgen deprovation therapy-linked cardiovascular 
disease risk: still unresolved. J Natl Cancer Inst 2015: 107(9).pii: djv268.
doi.:10.9093/jnci/djv268.
25. Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or 
without long-term androgen suppression for prostate cancer with high 
metastatic risk: 10-year results of an EORTC randomised study. Lancet 
Oncol 2010; 11: 1066–1073.
26. Efstathiou JA, Bae K, Shipley WU et al. Cardiovascular mortality and 
duration of androgen deprivation for locally advanced prostate cancer: 
analysis of RTOG 92-02. Eur Urol 2008; 54: 816–823.
27. Nguyen PL, Je Y, Schutz FA et al. Association of androgen deprivation 
therapy with cardiovascular death in patients with prostate cancer: 
a meta-analysis of randomized trials. JAMA 2011; 306: 2359–2366.
28. Voog JC, Paulus R, Shipley WU et al. Cardiovascular mortality following 
short-term androgen deprivation in clinically localized prostate cancer: 
an analysis of RTOG 94-08. Eur Urol 2016; 69: 204–210.
29. Cheung AS, Pattison D, Bretherton I et al. Cardiovascular risk and bone 
loss in men undergoing androgen deprivation therapy for non-meta-
static prostate cancer: implementation of standardized management 
guidelines. Andrology 2013; 1: 583–589.
30. Holmes-Walker DJ, Woo H, Gurney H et al. Maintaining bone health in 
patients with prostate cancer. Med J Aust 2006; 184: 176–179.
31. Morote J, Morin JO, Orsola A et al. Prevalence of osteoporosis during 
long-term androgen deprivation therapy in patients with prostate 
cancer. Urology 2007; 69: 500–504.
32. Saad F, Adachi JD, Brown JP et al. Cancer treatment-induced bone loss 
in breast and prostate cancer. J Cin Oncol 2008; 26: 5465–5476.
33. Serpa Neto A, Tobias-Machado M, Esteves MA et al. Bisphosphonate 
therapy in patients under androgen deprivation therapy for prostate 
cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic 
Dis 2012; 15: 36–44.
34. Lipton A, Smith MR, Ellis GK et al. Treatment-induced bone loss and frac-
tures in cancer patients undergoing hormone ablation therapy: efficacy 
and safety of denosumab. Clin Med Insights Oncology 2012; 6: 287–303.
35. Smith MR, Fallon MA, Lee H et al. Raloxifene to prevent gonado-
tropin-releasing hormone agonist-induced bone loss in men with 
prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 
2004; 89: 3841–3846.
36. Smith MR, Morton RA, Barnette KG et al. Toremifene to reduce fracture 
risk in men receiving androgen deprivation therapy for prostate cancer. 
J Urol 2013; 189 (1 Suppl): S45–50.
37. Pieńkowski T. Znaczenie inhibitorów aromatazy w leczeniu chorych na 
raka piersi OncoReview 2012; 22: 173–181.
38. Senkus-Konefka E. Hormonalne leczenie nowotworów. Stan obecny 
i perspektywy. Nowa Medycyna 2000 (10) http://www.czytelniame-
dyczna.pl/1506,hormonalne-leczenie-nowotworow-stan-obecny-i-
perspektywy.html.
39. Sobstyl M, Tkaczuk-Włach J, Sobstyl J et al. Objawy uboczne stosowania 
tamoksyfenu i raloksyfenu. Przegląd Menopauzalny 2012; 11: 250–253.
40. Wieczorek-Rutkowska M, Jassem J. Czynniki warunkujące skuteczność 
leczenia tamoksyfenem u chorych na raka piersi. Nowotwory J Oncol 
2010; 60: 42–49.
41. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in 
human liver. Cancer Res 1997; 57: 3402–3406.
42. Mani C, Kupfer D. Cytochrome P-450-mediated activation and irrevers-
ible binding of the antiestrogen tamoxifen to proteins in rat and human 
liver: possible involvement of flavin-containing monooxygenases in 
tamoxifen activation. Cancer Res 1991; 51: 6052–6058.
43. Johnson MD, Zuo H, Lee KH i et al. Pharmacological characterization 
of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of 
tamoxifen. Breast Cancer Res Treat 2004; 85: 151–159. 
44. Crewe HK, Ellis SW, Lennard MS et al. Variable contribution of cyto-
chromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen 
by human liver microsomes. Biochem Pharmacol 1997; 53: 171–178.
45. Desta Z, Ward BA, Soukhova NV et al. Comprehensive evaluation of 
tamoxifen sequential biotransformation by the human cytochrome 
P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Phar-
macol Exp Ther 2004; 310: 1062–1075.
46. Carpenter JS, Andrykowski MA, Cordova M et al. Hot flashes in post-
menopausal women treated for breast carcinoma: prevalence, severity, 
correlates, management, and relation to quality of life. Cancer 1998; 
82: 1682–1691.
47. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symp-
toms among women with a history of breast cancer and attitudes 
toward estrogen replacement therapy. J Clin Oncol 1995: 13: 2737–2744.
48. Carpenter JS, Johnson D, Wagner L et al. Hot flashes and related out-
comes in breast cancer survivors and matched comparison women. 
Oncol Nurs Forum 2002; 29: E16–25.
49. Avis NE. Breast cancer survivors and hot flashes: the search for nonhor-
monal treatments. J Clin Oncol 2008; 26: 5008–5010.
50. Kligman L, Yonus J. Management of hot flashes in women with breast 
cancer Curr Oncol 2010; 17: 81–86.
51. Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast 
cancer. Endocr Relat Cancer 2004; 11: 391–406.
52. Fallowfield LJ, Bliss JM, Porter LS et al. Quality of life in the intergroup 
exemestane study: a randomized trial of exemestane versus continued 
214
tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women 
with primary breast cancer. J Clin Oncol 2006; 24: 910–917.
53. Robert NJ, Goss PE, Ingle JN et al. Updated analysis of NCIC CTG MA.17 
(letrozole vs placebo to letrozole vs placebo) post unblinding. J Clin 
Oncol 2006; 24 (Suppl 18): 550. (Meeting Abstracts).
54. Stein KD, Jacobsen PB, Hann DM et al. Impact of hot flashes on quality 
of life among postmenopausal women being treated for breast cancer. 
J Pain Symptom Manage 2002; 19: 436–445.
55. Dorjgochoo T, Gu K, Kallianpur A et al. Menopausal symptoms among breast 
— libido cancer patients 6 months after cancer diagnosis: a report from the 
Shanghai Breast Cancer Survival Study. Menopause 2009; 16: 1205–1212.
56. Mourtis MJ, Bockermann I, de Vries EG et al.Tamoxifen effects on sub-
jective and psychosexual well-being, in a randomised breast cancer 
study comparing high-dose and standard-dose chemotherapy. Br J 
Cancer 2002; 86: 1546–1550.
57. Juozaitytė E, Aleknavičiusb E, Janciauskiene R et al. Guidelines for 
diagnostics and treatment of aromatase inhibitor-induced bone loss 
in women with breast cancer: a consensus of Lithuanian medical on-
cologists, radiation oncologists, endocrinologists, and family medicine 
physicians. Medicina 2014; 50: 197–203.
58. Hadji P. Cancer treatment-induced bone loss in women with breast 
cancer. Bonekey Rep 2015; 4: 692.
59. Ratajczak M, Sakowicz-Burkiewicz M, Kuczkowski J et al. Rola receptora 
aktywatora jądrowego czynnika kappa B (RANKL) oraz osteoprotegeryny 
(OPG) w rozwoju zębopochodnych torbieli i ziarniniaków okołowierz-
chołkowych kości szczęki i żuchwy. Nowa Stomatol 2013 (4): 187–190.
60. Hadji P, Aapro MS, Body JJ et al. Management of aromatase inhibi tor-
associated bone loss in postmenopausal women with breast cancer: 
practical guidance for prevention and treatment.   Ann Oncol 2011; 
22: 2546–2255.
61. Coleman R, Body J, Aapro M. Bone health in cancer patients: ESMO 
Clinical Practice Guidelines. Ann Oncol 2014; Suppl 3: iii124– iii137. 
62. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in 
tamoxifen-treated breast cancer patients, findings from the National 
Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer 
Inst 1994; 86: 527–537.
63.  Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer Study Group. 
Tamoxifen treatment for breast cancer and risk of rndometrial cancer: 
a case — control study. J Natl Cancer Inst 2005; 97: 375–384.
